Skip to Content
U.S. National Institutes of Health
Last Updated: 03/11/14

Diagnostics Evaluation Branch (DEB)

The Diagnostics Evaluation Branch (DEB) facilitates the development of markers and validation of innovative in vitro diagnostics to improve clinical outcomes for cancer patients.

  • Stimulating and supporting research to use in vitro diagnostics as prognostic markers to improve tumor classification and predictive markers to improve response to therapy.

  • Stimulating and supporting research on ELSI (ethical, legal and social implications) research considerations that include, but are not limited to: (i) informed consent, (ii) data access and data security, (iii) disclosure of research findings, and (iv) promoting community engagement of research participants.

  • Collaborating with other researchers and Government agencies to analytically and clinically validate in vitro diagnostics and their clinical utility.

DEB Staff:

Name Position Primary Email Phone
John Jessup, M.D. Branch Chief (240) 276-5952
Magdalena Thurin, Ph.D. Program Director (240) 276-5973
Kelly Kim, Ph.D. Program Director (240) 276-5938
Carol Weil, J.D. Program Director (240) 276-5975
Acquilly Lionel Administrative Support (240) 276-6005

For All CDP Staff